In August 2026, AstraZeneca and CSPC Pharmaceutical Group advanced their collaboration to develop biologics manufacturing capabilities in China, combining AstraZeneca’s global innovation and quality expertise with CSPC’s local pharmaceutical manufacturing strength to strengthen the country’s role in the global biopharmaceutical supply chain.
The partnership represents another example of multinational pharmaceutical companies expanding local manufacturing capabilities in China as biologics become an increasingly important growth area for the global healthcare industry.
Under the collaboration, AstraZeneca and CSPC plan to develop a new biologics manufacturing facility in Shijiazhuang, Hebei Province, focusing on advanced biologics production capabilities, including biologics drug substance manufacturing.
The project combines two complementary strengths:
AstraZeneca’s global experience in innovative medicines development, regulatory standards and international commercialization, together with CSPC’s established pharmaceutical manufacturing capabilities and local industrial infrastructure.
Biologics have become one of the fastest-growing segments of the pharmaceutical market.
Unlike traditional small-molecule medicines, biologic drugs require more complex manufacturing processes involving:
cell culture, protein expression, purification technologies, quality control systems and specialized supply chains.
As a result, reliable large-scale manufacturing capacity has become a critical competitive advantage for pharmaceutical companies.
China’s biopharmaceutical industry has developed rapidly over the past decade.
The country has moved beyond its traditional role as a manufacturing center and is becoming an increasingly important hub for:
innovative drug development, clinical research and commercial-scale production.
For multinational pharmaceutical companies, establishing local manufacturing capabilities can improve supply chain efficiency while supporting growing demand in China and across Asia.
AstraZeneca has continued to expand its long-term presence in China through investment in innovation, partnerships and local operations.
The collaboration with CSPC reflects a broader strategy among global pharmaceutical companies to strengthen manufacturing networks through regional partnerships.
For CSPC, the agreement further enhances its position in biologics and innovative pharmaceutical manufacturing.
The company has invested heavily in research platforms, production capabilities and international development, aiming to transition from a traditional pharmaceutical manufacturer into a more innovation-driven healthcare company.
The partnership is therefore not simply a manufacturing project, but a strategic move that connects Chinese pharmaceutical capabilities with the global biologics ecosystem.
The global pharmaceutical industry is currently undergoing a major supply chain transformation.
Companies in the United States and Europe are seeking greater supply chain resilience and reduced dependence on individual manufacturing regions.
At the same time, China’s mature manufacturing capabilities, engineering expertise and integrated pharmaceutical ecosystem are making it an increasingly important location for global biologics production.
The model of cooperation between multinational innovators and Chinese manufacturing leaders is expected to expand further.
Future opportunities are likely to emerge in areas including:
antibody therapies, biosimilars, antibody-drug conjugates (ADCs), cell therapies and next-generation protein medicines.
However, biologics manufacturing competition is not determined by capacity alone.
Companies must also maintain strong capabilities in:
manufacturing quality systems, process development, global regulatory compliance and international supply chain management.
For AstraZeneca and CSPC, the long-term value of the partnership will depend on how effectively they translate their combined strengths into globally competitive biologics manufacturing capabilities.
As China becomes increasingly integrated into the global pharmaceutical ecosystem, biologics manufacturing is emerging as a key area for international collaboration.
